<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial</h2>
    <div class="badge">2025-09-08T17:25:58+00:00</div>
    <ul>
      <li>Pharmaceuticals industry, which had an 11.5% decline.</li>
<li>market, which gained 20.8% over the past year, and the U.S.</li>
<li>This announcement likely played a key role in the company’s 16% share price rise over the past month.</li>
<li>Over the past five years, Eli Lilly&#x27;s total shareholder return, inclusive of share price appreciation and dividends, reached 416.18%, demonstrating significant longer-term performance.</li>
<li>Currently, the company&#x27;s shares trade at US$727.21, showing a considerable discount to the consensus price target of US$891.62, indicating potential room for upward correction should these growth drivers effectively mate</li>
<li>We&#x27;ve spotted 2 weaknesses for Eli Lilly you should be aware of, and 1 of them is a bit unpleasant.</li>
<li>This article by Simply Wall St is general in nature.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial\n• Pharmaceuticals industry, which had an 11.5% decline.\n• market, which gained 20.8% over the past year, and the U.S.\n• This announcement likely played a key role in the company’s 16% share price rise over the past month.\n• Over the past five years, Eli Lilly&#x27;s total shareholder return, inclusive of share price appreciation and dividends, reached 416.18%, demonstrating significant longer-term performance.\n• Currently, the company&#x27;s shares trade at US$727.21, showing a considerable discount to the consensus price target of US$891.62, indicating potential room for upward correction should these growth drivers effectively mate\n• We&#x27;ve spotted 2 weaknesses for Eli Lilly you should be aware of, and 1 of them is a bit unpleasant.\n• This article by Simply Wall St is general in nature." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/eli-lilly-lly-announces-promising-172558054.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>